Treating community-acquired lower respiratory infection.
Despite the proliferation of antibiotics, pneumonia remains a leading cause of death in the United States. Diagnostic methods for identifying pathogenic organisms in pneumonia frequently are inaccurate or unreliable, and may be unproductive. When the precise etiology has not been determined, a second-generation cephalosporin offers wide antibiotic coverage as initial therapy for patients with community-acquired bacterial pneumonia.